137 results on '"Miravitlles, Marc"'
Search Results
2. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice
3. Mortality and readmission after COPD exacerbation-related hospitalization: an individual patient data meta-analysis
4. Alpha-1 antitrypsin Pi*SS genotype and risk of pulmonary disease. An EARCO Research project
5. Impact of duration of inhaled antibiotic treatment in COPD patients with chronic bronchial infection by Pseudomonas
6. Identification of disease modifier genetic variants in PiZZ patients with alpha-1 antitrypsin deficiency
7. Enhanced liver fibrosis (ELF) test as a biomarker of pulmonary fibrosis (PF) secondary to COVID-19 pneumonia.
8. Blood biomarkers in patients with Alpha-1 Antitrypsin Deficiency from the EARCO CRC Registry
9. Impact of COVID-19 on patients with PiZZ alpha1-antitrypsin deficiency: the IMCA1 study revisited.
10. Elastase inhibitory activity (EIA) in Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD)
11. Tolerance to inhaled antibiotic therapy in COPD patients and chronic bronchial infection by Pseudomonas
12. Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients.
13. From treatable traits to GETomics in airway disease: moving towards clinical practice.
14. Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint.
15. Clinical approach to the diagnosis and assessment of AATD
16. Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry
17. External quality assessment (EQA) for laboratory diagnosis of alpha1-antitrypsin deficiency (AATD) – Program driven by the European Alpha-1-Research Collaboration (EARCO) network
18. The burden of COPD in young individuals: results from EPISCAN II
19. Baseline characteristics of patients enrolled in the EARCO prospective registry of alpha-1 antitrypsin deficiency: preliminary results
20. Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients
21. Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD)
22. Late Breaking Abstract - Impact of COVID-19 on patients with severe alpha1 antitrypsin deficiency: the IMCA1 study of the EARCO ERS Clinical Research Collaboration, preliminary findings
23. Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards [editorial]
24. Introduction
25. Impact of chronic bronchial infection on the lungs and beyond
26. Infective exacerbations of COPD
27. Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews.
28. Research priorities in alpha-1 antitrypsin deficiency (AATD) for healthcare professionals
29. Sex differences in COPD outcome in 5,355 women with COPD: A new analysis of the 3CIA study
30. Burden of disease among exacerbating patients with eosinophil COPD treated with triple therapy in Spain
31. How to get the most out of the ERS International Congress 2021 and an overview of the Early Career Member session.
32. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD.
33. Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients
34. Routine blood test biomarkers and their association with exacerbations in COPD
35. Nutritional status and physical activity in patients with COPD, and factors associated with malnutrition
36. Risk charts of five-year mortality in COPD patients
37. Bone health of patients with COPD in relation to their exercise capacity and gait speed
38. Structural and clinical characterization of novel missense variants of SERPINA1 gene causing alpha-1 antitrypsin deficiency
39. Late Breaking Abstract - A New study of the Prevalence of COPD in Spain: EPISCAN II
40. Assessing the impact of COPD on sleep quality with the CASIS questionnaire
41. Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review.
42. VALIDATION OF AN ASSESSMENT TOOL FOR CONTROL IN COPD: ANALYSIS OF CLINICAL VARIABLES.
43. Screening of chronic liver disease by transient elastography in patients with lung disease associated with alpha-1 antitrypsin deficiency.
44. The Capacity of Daily Living during the Morning (CDLM) questionnaire: Evaluating the impact of morning symptoms in COPD
45. Characterization of patients with severe COPD
46. Neutrophil elastase gene expression and relation with lung function in Alpha-1 Antitrypsin deficiency patients
47. Identifying cut off scores for the chronic obstructive pulmonary disease assessment test (CAT) to predict exacerbations in COPD
48. Cardiovascular comorbidity in severe COPD patients
49. Adherence to inhaled therapies in COPD patients from 7 Latin America countries: the LASSYC study
50. Gene expression network in PiZZ Alpha1 Antitrypsin Deficiency and its relationship with the severity of lung disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.